Sendero Wealth Management LLC Buys 3,395 Shares of Danaher Corporation $DHR

Sendero Wealth Management LLC raised its stake in Danaher Corporation (NYSE:DHR) by 84.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,439 shares of the conglomerate’s stock after purchasing an additional 3,395 shares during the quarter. Sendero Wealth Management LLC’s holdings in Danaher were worth $1,475,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. WFA of San Diego LLC bought a new stake in Danaher during the 2nd quarter valued at $26,000. Howard Hughes Medical Institute purchased a new position in shares of Danaher in the second quarter valued at about $27,000. Red Tortoise LLC raised its stake in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 98 shares during the last quarter. Heartwood Wealth Advisors LLC purchased a new stake in shares of Danaher during the third quarter worth about $37,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Danaher in the second quarter worth about $40,000. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,248 shares of company stock worth $6,609,663 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Shares of NYSE DHR opened at $222.91 on Thursday. The company has a 50 day simple moving average of $219.53 and a two-hundred day simple moving average of $206.53. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a market capitalization of $157.45 billion, a price-to-earnings ratio of 45.96, a P/E/G ratio of 4.36 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the firm posted $1.71 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio is currently 26.39%.

Wall Street Analyst Weigh In

A number of analysts recently commented on DHR shares. The Goldman Sachs Group started coverage on Danaher in a research note on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price target for the company. HSBC raised their price objective on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Barclays lifted their price objective on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Finally, Robert W. Baird set a $247.00 price target on Danaher in a research report on Wednesday, October 22nd. Twenty equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $248.25.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.